Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 560

1.

Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells.

Konforte D, Simard N, Paige CJ.

Virology. 2008 Apr 25;374(1):100-13. doi: 10.1016/j.virol.2007.12.027. Epub 2008 Jan 28.

2.

Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS.

Blood. 1995 Jul 15;86(2):659-65.

3.
4.

c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.

Polack A, Hörtnagel K, Pajic A, Christoph B, Baier B, Falk M, Mautner J, Geltinger C, Bornkamm GW, Kempkes B.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10411-6.

6.
9.

Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.

Trivedi P, Spinsanti P, Cuomo L, Volpe M, Takada K, Frati L, Faggioni A.

J Virol. 2001 May;75(10):4929-35.

10.

IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.

Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, Klein G, Klein E.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):872-7. doi: 10.1073/pnas.0912920107. Epub 2009 Dec 22.

11.

Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2.

Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, Farrell PJ.

J Virol. 2008 Aug;82(15):7456-66. doi: 10.1128/JVI.00223-08. Epub 2008 May 14.

12.

Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells.

Kuhn-Hallek I, Sage DR, Stein L, Groelle H, Fingeroth JD.

Blood. 1995 Mar 1;85(5):1289-99.

13.

Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a.

Motsch N, Pfuhl T, Mrazek J, Barth S, Grässer FA.

RNA Biol. 2007 Nov;4(3):131-7.

PMID:
18347435
14.

Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells.

Pagès F, Galon J, Karaschuk G, Dudziak D, Camus M, Lazar V, Camilleri-Broët S, Lagorce-Pagès C, Lebel-Binay S, Laux G, Fridman WH, Henglein B.

Blood. 2005 Feb 15;105(4):1632-9. Epub 2004 Oct 21.

15.

The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.

Xu ZG, Iwatsuki K, Oyama N, Ohtsuka M, Satoh M, Kikuchi S, Akiba H, Kaneko F.

Br J Cancer. 2001 Apr 6;84(7):920-5.

17.

Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.

Larcher C, Bernhard D, Schaadt E, Adler B, Ausserlechner MJ, Mitterer M, Huemer HP.

Haematologica. 2003 Dec;88(12):1324-35.

18.

Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway.

Dudziak D, Kieser A, Dirmeier U, Nimmerjahn F, Berchtold S, Steinkasserer A, Marschall G, Hammerschmidt W, Laux G, Bornkamm GW.

J Virol. 2003 Aug;77(15):8290-8.

19.

Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.

Fåhraeus R, Palmqvist L, Nerdstedt A, Farzad S, Rymo L, Laín S.

EMBO J. 1994 Dec 15;13(24):6041-51.

20.

Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.

Brink AA, Dukers DF, van den Brule AJ, Oudejans JJ, Middeldorp JM, Meijer CJ, Jiwa M.

J Clin Pathol. 1997 Nov;50(11):911-8.

Supplemental Content

Support Center